Numinus CEO Discusses Latest Earnings

We’re back with CEO of Numinus Wellness (TSX: NUMI) Payton Nyquvest who shares their Q2 financial results this year that puts Numinus in a stronger market position and proves their continuous success in the space and becoming the leading company in terms of psychedelic-assisted clinics.

We also dive deeper into their recent announcement about their new licensing model that will offer independent practitioners to operate under their top-of-line service agreement. Their expertise in the psychedelic-assisted therapies including Numinus’ Ketamine Clinics probe to have significantly higher outcomes as walk-ins and patient retention rise. We discuss how these expansions are bridging the gaps in mental health treatments.

In addition, Payton reveals their company’s competitive edge on strengthening patients and practitioners’ education about these new treatments and clinical models, and we further elaborate the key components to establishing their clinical model, and how it differs versus other company’s approaches. How does this affect the overall perspective about the industry and is this a noteworthy proposition to invest in the space now?

Hosted on Acast. See acast.com/privacy for more information.